Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group a, c, w-135 and y tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **quadrivalent conjugate vaccine** formulated to protect against invasive disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. Each of the four capsular polysaccharides is individually conjugated to a **tetanus toxoid protein carrier**, improving immunogenicity especially in infants and young children. The vaccine induces active immunity by promoting the production of specific IgG, IgM, and IgA antibodies targeting the capsular antigens of these serogroups, thus enabling bactericidal activity against *N. meningitidis*. It is not adjuvanted and does not contain preservatives. MenACWY-TT is indicated for active immunization of individuals as young as 12 months (Europe) or 2 years (USA), with a well-characterized safety and immunogenicity profile.
- Brand names
- NimenrixMenQuadfi
- Other names
- meningococcal groups a, c, y and w-135 polysaccharide tetanus toxoid conjugate vaccineserogroups a, c, w-135, and y tetanus toxoid conjugate vaccineMenACWY-TT
02
Targets
TT (Tetanus toxoid)Neuraminidase
Beyond the preview
Go deeper on meningococcal group a, c, w-135 and y tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group a, c, w-135 and y tetanus toxoid conjugate vaccine.